Dilly S
SmithKline Beecham Pharmaceuticals, Surrey, U.K.
Eur J Cancer. 1992;28A Suppl 1:S32-5. doi: 10.1016/0959-8049(92)90634-e.
There are no published direct trials of granisetron vs. ondansetron. Difficulties exist in comparing reported trials because of differences in methodology, especially in response criteria. In this review, a comparison is made between ondansetron and granisetron by recalculating the complete response criterion for granisetron, standardising it against that in the ondansetron programme (i.e. no vomiting). Weighted means have been calculated for three areas of study. Against cisplatin-induced emesis the (weighted) mean percentage of complete responders were calculated at 64% (range 49-77%) for granisetron and 49% (range 40-55%) for ondansetron. Against moderately emetogenic stimuli, the response rates were 76% (range 68-80%) and 73% (range 60-87%) respectively. For fractionated chemotherapy the response rates were 57% and 27% for granisetron and ondansetron respectively. Although not shown by formal statistical analysis, these results suggest that a clinical advantage for granisetron may exist.
目前尚无已发表的关于格拉司琼与昂丹司琼对比的直接试验。由于方法学上的差异,尤其是在反应标准方面,对已报道的试验进行比较存在困难。在本综述中,通过重新计算格拉司琼的完全缓解标准,并将其与昂丹司琼方案中的标准(即无呕吐)进行标准化对比,对昂丹司琼和格拉司琼进行了比较。已针对三个研究领域计算了加权均值。对于顺铂引起的呕吐,格拉司琼的完全缓解者(加权)平均百分比计算为64%(范围49 - 77%),昂丹司琼为49%(范围40 - 55%)。对于中度致吐刺激,缓解率分别为76%(范围68 - 80%)和73%(范围60 - 87%)。对于分次化疗,格拉司琼和昂丹司琼的缓解率分别为57%和27%。尽管未通过正式的统计分析表明,但这些结果提示格拉司琼可能具有临床优势。